UNSPSC 51383902: Clonixin

This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C13H11ClN2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier V7DXN0M42R, chemically known as 3-pyridinecarboxylic acid, 2-((3-chloro-2-methylphenyl)amino)- but generally known as clonixin, which bears US NIH Compound Identifier 28718. European Medicines Agency schedules Clonixin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06734MIG. The term CLONIXIN is an International Non-Proprietary Name.

UNSPSC 51383902 Clonixin, a Commodity code, does not align with the pharmaceutical procurement activity currently being solicited under this classification by state and local governments. The recent opportunities tagged to this code involve naloxone and drug deactivation systems, generic multi-source pharmaceuticals and over-the-counter products, and direct-to-manufacturer prescription programs — none of which are clonixin-specific products. The code shows little relevant recent activity that maps to its nominal scope.

State and local issuing bodies entering the pharmaceutical market include county health departments (Seminole County, Florida), state health and human services agencies (Texas Health and Human Services Commission), and multi-state cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance serving Minnesota and Oregon). The recent opportunities show a mix of small tactical procurements and larger multi-jurisdictional framework agreements, with the Minnesota MMCAP RFP for generic multi-source pharmaceuticals and OTC products posted January 20, 2026 with a March 26, 2026 response deadline, and Seminole County's IFB for naloxone and drug deactivation systems posted June 30, 2026 with a July 26, 2023 response deadline. The Texas HHS RFI on direct-to-manufacturer prescriptions, posted April 3, 2026, represents preliminary market research rather than a formal competitive solicitation. Given the mismatch between the code's intended scope and the actual procurements tagged to it, business development professionals should verify the correct UNSPSC classification for pharmaceutical products before investing pursuit resources.